1. < Prostate Cancer
Profile picture for Jeff Marchi

Meeting for those with genetic mutations

Posted by Jeff Marchi @jeffmarc, Jan 7 12:33pm

Ancan.Org is having a meeting for people with genetic mutations this Thursday at 8 PM Eastern time 5 PM Pacific. Any type of genetic mutation is welcome as well as those with sickle cell.

If you’d like a chance to talk to people that are knowledgeable about these issues and others that have them, this would be a good place to meet.

You do have to install GoTo Meeting on your device and the meeting name is ancanschmier to join.

Interested in more discussions like this? Go to the Prostate Cancer Support Group.

Profile picture for denis76
denis76 | @denis76 | Jan 13 12:28am
In reply to @wilkinson1ski "Looks like I misinterpreted that ADT was not as effective from the beginning, but it seems..." + (show)
Profile picture for wilkinson1ski @wilkinson1ski

Looks like I misinterpreted that ADT was not as effective from the beginning, but it seems to say that it is a good first step but ATM will generally become hormone resistant quicker at which time ADT could worsen outcomes.

Here's the paper title:
Hwang, et al (2023) Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

ChatGPT summary
What this paper studied (in simple terms). This study was based on real-world treatment data, not a lab experiment or a drug trial.
Researchers looked at 1,187 men with metastatic prostate cancer and compared cancers with:
ATM mutations
BRCA2 mutations
Other DNA-repair mutations
No DNA-repair mutations

They asked two main questions:
Do ATM-mutated prostate cancers behave differently from BRCA2-mutated ones?
How do these cancers respond to hormone treatments like ADT and newer androgen-targeted drugs (abiraterone, enzalutamide)?

Key finding in one sentence (ATM + ADT)
Prostate cancers with an ATM mutation tend to respond normally to ADT at first, but once the cancer becomes castration-resistant, outcomes on continued hormone-based therapies are worse than average.

If someone has ATM-mutated prostate cancer:
ADT is still the right first step
But doctors should expect:
Earlier hormone resistance
Reduced benefit from long-term hormone-only strategies
Treatment planning may need:
Earlier consideration of non-hormonal options
Different targeted strategies (not PARP inhibitors alone)

Jump to this post

@wilkinson1ski

I wouldn't trust such complex questions to the GPT chat....

REPLY
Profile picture for wilkinson1ski
wilkinson1ski | @wilkinson1ski | Jan 13 1:45pm

Thanks Jeff and Denis, we're not completely relying on ChatGPT - we're reading the papers ourselves and sending them to our medical team. We are doing our best to make sense of the lastest research available since our very busy doctors don't have time to do this for us but they are willing to look at papers and help us to apply it to our situation.

My husband's Artera AI came back - it looks like while the report recommended for his specific case that he should undergo ADT at least during radiation that he was "Likely to benefit less from Abiratone: on average, patients iwth this result had no clear improvement in MFS or PCSM risk reduction with the addition of abiraterone to ADT +/- RT.

So glad we had the test done!

REPLY
View MoreView Less
Please sign in or register to post a reply.